Venture Global (VG) Is Up 24.3% After Strong Q1 Beat And New LNG Contracts With Majors

Venture Global

Venture Global

VG

0.00

  • In the first quarter of 2026, Venture Global, Inc. reported sales of US$4.60 billion and net income of US$598 million, with earnings per share exceeding analyst estimates and management lifting its 2026 consolidated Adjusted EBITDA guidance.
  • At the same time, Venture Global secured new multi‑year LNG supply agreements with TotalEnergies and Vitol, adding over 1 million tonnes per year of contracted volumes that reinforce the company’s growing role in global LNG trade.
  • Now we’ll examine how these stronger‑than‑expected results and new TotalEnergies contract may influence Venture Global’s existing investment narrative.

Uncover the next big thing with 24 elite penny stocks that balance risk and reward.

Venture Global Investment Narrative Recap

To own Venture Global today, you need to believe its rapid build out of Plaquemines and CP2 will translate into sustained LNG volumes and solid cash generation, while construction risk and LNG price volatility remain the key swing factors. The Q1 2026 beat and higher Adjusted EBITDA guidance support the near term volume and earnings catalyst, but they do little to reduce the longer term risks around project execution, cost discipline and potential arbitration outcomes.

The new multi year LNG agreements with TotalEnergies and Vitol look most relevant here, because they add more than 1 million tonnes per year of contracted volumes starting in 2026. That reinforces one of the core positives in the Venture Global story: growing contracted coverage that can help underpin cash flows as Plaquemines and CP2 ramp, even while the market debates how much short and medium term exposure could still leave earnings sensitive to future LNG price swings.

Yet even against this strong quarter, investors should be aware of how unresolved arbitration and potential cash outflows could still...

Venture Global's narrative projects $19.0 billion revenue and $1.8 billion earnings by 2028. This requires 20.6% yearly revenue growth and a $0.3 billion earnings decrease from $2.1 billion today.

Uncover how Venture Global's forecasts yield a $12.26 fair value, a 14% downside to its current price.

Exploring Other Perspectives

VG 1-Year Stock Price Chart
VG 1-Year Stock Price Chart

Some of the lowest analysts were far more cautious, assuming revenue of about US$15.5 billion and earnings of only US$72 million by 2028, with thinner margins. If you lean toward that more pessimistic view, or worry that a larger mix of shorter contracts could amplify price swings, these latest results and new TotalEnergies volumes might prompt you to revisit how much risk you are truly comfortable with and which scenario feels more realistic for you.

Explore 8 other fair value estimates on Venture Global - why the stock might be worth 37% less than the current price!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

  • A great starting point for your Venture Global research is our analysis highlighting 3 key rewards and 3 important warning signs that could impact your investment decision.
  • Our free Venture Global research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Venture Global's overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

  • The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 16 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
  • Find 49 companies with promising cash flow potential yet trading below their fair value.
  • AI is about to change healthcare. These 32 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.